216 related articles for article (PubMed ID: 12419016)
21. Model for the drug-drug interaction responsible for CYP3A enzyme inhibition. I: evaluation of cynomolgus monkeys as surrogates for humans.
Kanazu T; Yamaguchi Y; Okamura N; Baba T; Koike M
Xenobiotica; 2004 May; 34(5):391-402. PubMed ID: 15370956
[TBL] [Abstract][Full Text] [Related]
22. Comparative studies of in vitro inhibition of cytochrome P450 3A4-dependent testosterone 6beta-hydroxylation by roxithromycin and its metabolites, troleandomycin, and erythromycin.
Yamazaki H; Shimada T
Drug Metab Dispos; 1998 Nov; 26(11):1053-7. PubMed ID: 9806945
[TBL] [Abstract][Full Text] [Related]
23. Formation in vitro of an inhibitory cytochrome P450 x Fe2+-metabolite complex with roxithromycin and its decladinosyl, O-dealkyl and N-demethyl metabolites in rat liver microsomes.
Yamazaki H; Shimada T
Xenobiotica; 1998 Oct; 28(10):995-1004. PubMed ID: 9849646
[TBL] [Abstract][Full Text] [Related]
24. Stereoselective metabolism of endosulfan by human liver microsomes and human cytochrome P450 isoforms.
Lee HK; Moon JK; Chang CH; Choi H; Park HW; Park BS; Lee HS; Hwang EC; Lee YD; Liu KH; Kim JH
Drug Metab Dispos; 2006 Jul; 34(7):1090-5. PubMed ID: 16581944
[TBL] [Abstract][Full Text] [Related]
25. Diltiazem inhibits human intestinal cytochrome P450 3A (CYP3A) activity in vivo without altering the expression of intestinal mRNA or protein.
Pinto AG; Horlander J; Chalasani N; Hamman M; Asghar A; Kolwankar D; Hall SD
Br J Clin Pharmacol; 2005 Apr; 59(4):440-6. PubMed ID: 15801939
[TBL] [Abstract][Full Text] [Related]
26. Interactions of tamoxifen, N-desmethyltamoxifen and 4-hydroxytamoxifen with P-glycoprotein and CYP3A.
Bekaii-Saab TS; Perloff MD; Weemhoff JL; Greenblatt DJ; von Moltke LL
Biopharm Drug Dispos; 2004 Oct; 25(7):283-9. PubMed ID: 15386482
[TBL] [Abstract][Full Text] [Related]
27. Microsomal metabolism of delavirdine: evidence for mechanism-based inactivation of human cytochrome P450 3A.
Voorman RL; Maio SM; Payne NA; Zhao Z; Koeplinger KA; Wang X
J Pharmacol Exp Ther; 1998 Oct; 287(1):381-8. PubMed ID: 9765359
[TBL] [Abstract][Full Text] [Related]
28. Human cytochrome P450 3A4-catalyzed testosterone 6 beta-hydroxylation and erythromycin N-demethylation. Competition during catalysis.
Wang RW; Newton DJ; Scheri TD; Lu AY
Drug Metab Dispos; 1997 Apr; 25(4):502-7. PubMed ID: 9107550
[TBL] [Abstract][Full Text] [Related]
29. Comparison of steroid hormone hydroxylation mediated by cytochrome P450 3A subfamilies.
Niwa T; Okamoto A; Narita K; Toyota M; Kato K; Kobayashi K; Sasaki S
Arch Biochem Biophys; 2020 Mar; 682():108283. PubMed ID: 32001245
[TBL] [Abstract][Full Text] [Related]
30. Oxidative metabolism of clarithromycin in the presence of human liver microsomes. Major role for the cytochrome P4503A (CYP3A) subfamily.
Rodrigues AD; Roberts EM; Mulford DJ; Yao Y; Ouellet D
Drug Metab Dispos; 1997 May; 25(5):623-30. PubMed ID: 9152603
[TBL] [Abstract][Full Text] [Related]
31. Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4'-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen.
Crewe HK; Notley LM; Wunsch RM; Lennard MS; Gillam EM
Drug Metab Dispos; 2002 Aug; 30(8):869-74. PubMed ID: 12124303
[TBL] [Abstract][Full Text] [Related]
32. Biotransformation of parathion in human liver: participation of CYP3A4 and its inactivation during microsomal parathion oxidation.
Butler AM; Murray M
J Pharmacol Exp Ther; 1997 Feb; 280(2):966-73. PubMed ID: 9023313
[TBL] [Abstract][Full Text] [Related]
33. Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro.
Granfors MT; Wang JS; Kajosaari LI; Laitila J; Neuvonen PJ; Backman JT
Basic Clin Pharmacol Toxicol; 2006 Jan; 98(1):79-85. PubMed ID: 16433896
[TBL] [Abstract][Full Text] [Related]
34. Model for the drug-drug interaction responsible for CYP3A enzyme inhibition. II: establishment and evaluation of dexamethasone-pretreated female rats.
Kanazu T; Yamaguchi Y; Okamura N; Baba T; Koike M
Xenobiotica; 2004 May; 34(5):403-13. PubMed ID: 15370957
[TBL] [Abstract][Full Text] [Related]
35. Contribution of CYP3A4, CYP2B6, and CYP2C9 isoforms to N-demethylation of ketamine in human liver microsomes.
Hijazi Y; Boulieu R
Drug Metab Dispos; 2002 Jul; 30(7):853-8. PubMed ID: 12065445
[TBL] [Abstract][Full Text] [Related]
36. Evidence for involvement of human CYP3A in the 3-hydroxylation of quinine.
Zhang H; Coville PF; Walker RJ; Miners JO; Birkett DJ; Wanwimolruk S
Br J Clin Pharmacol; 1997 Mar; 43(3):245-52. PubMed ID: 9088578
[TBL] [Abstract][Full Text] [Related]
37. Role of a potent inhibitory monoclonal antibody to cytochrome P-450 3A4 in assessment of human drug metabolism.
Mei Q; Tang C; Assang C; Lin Y; Slaughter D; Rodrigues AD; Baillie TA; Rushmore TH; Shou M
J Pharmacol Exp Ther; 1999 Nov; 291(2):749-59. PubMed ID: 10525096
[TBL] [Abstract][Full Text] [Related]
38. Investigation of the major human hepatic cytochrome P450 involved in 4-hydroxylation and N-dechloroethylation of trofosfamide.
May-Manke A; Kroemer H; Hempel G; Bohnenstengel F; Hohenlöchter B; Blaschke G; Boos J
Cancer Chemother Pharmacol; 1999; 44(4):327-34. PubMed ID: 10447581
[TBL] [Abstract][Full Text] [Related]
39. Metabolism of alfentanil by cytochrome p4503a (cyp3a) enzymes.
Klees TM; Sheffels P; Dale O; Kharasch ED
Drug Metab Dispos; 2005 Mar; 33(3):303-11. PubMed ID: 15557344
[TBL] [Abstract][Full Text] [Related]
40. Quantitative prediction of macrolide drug-drug interaction potential from in vitro studies using testosterone as the human cytochrome P4503A substrate.
Polasek TM; Miners JO
Eur J Clin Pharmacol; 2006 Mar; 62(3):203-8. PubMed ID: 16416302
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
